NC
NBIX icon

NewSquare Capital’s Neurocrine Biosciences NBIX Stock Holding History

NewSquare Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-74
Closed -$9.3K – 846
2025
Q2 		$9.3K Buy
+74
New +$8.49K ﹤0.01% 668
2025
Q1 		– Sell
-7
Closed -$956 – 1212
2024
Q4 		$956 Buy
+7
New +$866 ﹤0.01% 667
2023
Q3 		– Sell
-6
Closed -$566 – 787
2023
Q2 		$566 Hold
6
– – ﹤0.01% 674
2023
Q1 		$607 Hold
6
– – ﹤0.01% 695
2022
Q4 		$717 Buy
+6
New +$703 ﹤0.01% 617

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewSquare Capital's NBIX Position: Q3 2025 in Review

NewSquare Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 74 shares — an estimated $9.3K sold.

NewSquare Capital first reported a position in NBIX in Q4 2022 and held it in 5 quarters. The position peaked at $9.3K in Q2 2025. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • NewSquare Capital reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • NewSquare Capital sold 74 Neurocrine Biosciences shares in Q3 2025, an estimated $9.3K.
  • NewSquare Capital first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 5 quarters.
  • NewSquare Capital's Neurocrine Biosciences position peaked at $9.3K in Q2 2025.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on NewSquare Capital's 13F filing for Q3 2025, filed 12 Nov 2025.